At a glance
ClinicalIndex Comparison Record- ✓Age 50 years or older
- ✓Meet criteria for either amnestic mild cognitive impairment (MCI) (single or mixed domain) or mild Alzheimer's disease (AD), or have no cognitive impairment
- ✓For MCI and mild AD: Clinical Dementia Rating scale score of 0.5 or 1; for unimpaired subjects: score of 0
- ✓Able to participate in all scheduled evaluations and complete all required tests and procedures
- ✕Past or present history of certain brain disorders other than MCI or AD
- ✕Significant medical conditions making study procedures unsafe, including uncontrolled epilepsy and multiple serious injuries
- ✕Contraindication to MRI scanning
- ✕Conditions precluding entry into scanners (e.g., morbid obesity, claustrophobia)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Imaging Tau in Alzheimer's Disease and Normal Aging With 18F-MK-6240
In Brief
A Phase 2 clinical trial evaluating 18F-MK-6240 and Lumbar Puncture (optional) for Alzheimer Disease. Completed, enrolled 71 participants across 1 site.
Detailed Summary
This study is being done to learn about tau tangles in Alzheimer's disease. A type of positron emission tomography (PET) scan is used to measure the abnormal accumulation of protein called tau in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and to tests to measure the participant's memory and thinking.
Study Details
Timeline
Interventions
18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.